{"id":684,"date":"2026-04-12T18:17:27","date_gmt":"2026-04-12T18:17:27","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&p=684"},"modified":"2026-08-30T03:53:26","modified_gmt":"2026-08-30T03:53:26","slug":"lucirux-ruxolitinib-20mgx60-tablets","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/pt\/product\/lucirux-ruxolitinib-20mgx60-tablets\/","title":{"rendered":"LuciRux 20mg"},"content":{"rendered":"

HIGHLIGHTS OF PRESCRIBING INFORMATION<\/span><\/p>\n

These highlights do not include all the information needed to use LuciRux safely and effectively. See full prescribing information for LuciRux.<\/span><\/p>\n

 <\/span><\/p>\n

INDICATIONS AND USAGE<\/strong><\/strong><\/span><\/p>\n

Jakafi is a kinase inhibitor indicated for treatment of:<\/span><\/p>\n

\u2022 intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults.<\/span><\/p>\n

\u2022 polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea.  <\/span><\/p>\n

\u2022 steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.<\/span><\/p>\n

\u2022 chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE AND ADMINISTRATION<\/strong><\/strong><\/span><\/p>\n

Doses should be individualized based on safety and efficacy. Starting doses per indication are noted below.<\/span><\/p>\n

Myelofibrosis<\/span><\/p>\n

\u2022 The starting dose of Jakafi is based on patient\u2019s baseline platelet count:<\/span><\/p>\n

\u2022 Greater than 200 \u00d7 109<\/span><\/sup>\/L: 20 mg given orally twice daily<\/span><\/p>\n

\u2022 100 \u00d7 109<\/span><\/sup>\/L to 200 \u00d7 109<\/span><\/sup>\/L: 15 mg given orally twice daily<\/span><\/p>\n

\u2022 50 \u00d7 109<\/span><\/sup>\/L to less than 100 \u00d7 109<\/span><\/sup>\/L: 5 mg given orally twice daily<\/span><\/p>\n

\u2022 Monitor complete blood counts every 2 to 4 weeks until doses are stabilized, and then as clinically indicated. Modify or interrupt dosing for thrombocytopenia.<\/span><\/p>\n

Polycythemia Vera<\/span><\/p>\n

\u2022 The starting dose of Jakafi is 10 mg given orally twice daily.<\/span><\/p>\n

Acute Graft-Versus-Host Disease<\/span><\/p>\n

\u2022 The starting dose of Jakafi is 5 mg given orally twice daily.<\/span><\/p>\n

Chronic Graft-Versus-Host Disease<\/span><\/p>\n

\u2022 The starting dose of Jakafi is 10 mg given orally twice daily.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE FORMS AND STRENGTHS<\/strong><\/strong><\/span><\/p>\n

Tablets: 20mg\u00d760 tablets<\/span><\/p>\n

 <\/span><\/p>\n

CONTRAINDICATIONS<\/strong><\/strong><\/span><\/p>\n

None<\/span><\/p>\n

 <\/span><\/p>\n

WARNINGS AND PRECAUTIONS<\/strong><\/strong><\/span><\/p>\n

\u2022 Thrombocytopenia, Anemia and Neutropenia: Manage by dose reduction, or interruption, or transfusion.<\/span><\/p>\n

\u2022 Risk of Infection: Assess patients for signs and symptoms of infection and initiate appropriate treatment promptly. Serious infections should have resolved before starting therapy with Jakafi.<\/span><\/p>\n

\u2022 Symptom Exacerbation Following Interruption or Discontinuation: Manage with supportive care and consider resuming treatment with Jakafi.<\/span><\/p>\n

\u2022 Risk of Non-Melanoma Skin Cancer: Perform periodic skin examinations.  <\/span><\/p>\n

\u2022 Lipid Elevations: Assess lipid levels 8-12 weeks from start of therapy and treat as needed.<\/span><\/p>\n

\u2022 Major Adverse Cardiovascular Events (MACE): Monitor for development of MACE.<\/span><\/p>\n

\u2022 Thrombosis: Evaluate and treat symptoms of thrombosis promptly.<\/span><\/p>\n

\u2022 Secondary Malignancies: Monitor for development of secondary malignancies, particularly in patients who are current or past smokers.<\/span><\/p>\n

 <\/span><\/p>\n

ADVERSE REACTIONS<\/strong><\/strong><\/span><\/p>\n

\u2022 In myelofibrosis and polycythemia vera, the most common hematologic adverse reactions (incidence > 20%) are thrombocytopenia and anemia. The most common nonhematologic adverse reactions (incidence \u2265 15%) are bruising, dizziness, headache, and diarrhea.<\/span><\/p>\n

\u2022 In acute graft-versus-host disease, the most common hematologic adverse reactions (incidence > 50%) are anemia, thrombocytopenia, and neutropenia. The most common nonhematologic adverse reactions (incidence > 50%) are infections (pathogen not specified) and edema.  <\/span><\/p>\n

\u2022 In chronic graft-versus-host disease, the most common hematologic adverse reactions (incidence > 35%) are anemia and thrombocytopenia. The most common nonhematologic adverse reactions (incidence \u2265 20%) are infections (pathogen not specified) and viral infections.<\/span><\/p>\n

 <\/span><\/p>\n

DRUG INTERACTIONS<\/strong><\/strong><\/span><\/p>\n

\u2022 Fluconazole: Avoid concomitant use with fluconazole doses greater than 200 mg. Reduce Jakafi dosage with fluconazole doses less than or equal to 200 mg.<\/span><\/p>\n

\u2022 Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue Jakafi doses as recommended except in patients with acute or chronic graftversus-host-disease.<\/span><\/p>\n

 <\/span><\/p>\n

USE IN SPECIFIC POPULATIONS<\/strong><\/strong><\/span><\/p>\n

\u2022 Renal Impairment: Reduce Jakafi starting dose or avoid treatment as recommended.<\/span><\/p>\n

\u2022 Hepatic Impairment: Reduce Jakafi starting dose or avoid treatment as recommended.<\/span><\/p>\n

\u2022 Lactation: Advise not to breastfeed.<\/span><\/p>\n

 <\/span><\/p>\n

Storage<\/strong><\/strong><\/span><\/p>\n

Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F), excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture. <\/span><\/p>\n

<\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

LuciRux is a kinase inhibitor indicated for treatment of: \u2022 intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults.<\/p>","protected":false},"featured_media":1880,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[32],"product_tag":[],"class_list":["post-684","product","type-product","status-publish","has-post-thumbnail","product_cat-graft-versus-host-disease","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product\/684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/comments?post=684"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/media\/1880"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/media?parent=684"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_brand?post=684"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_cat?post=684"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_tag?post=684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}